Migraine - Inflammatory Cocktail Model
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Headache disorders consistently rank as one of the most prevalent neurological conditions globally, with migraine being one of the most disabling disorders. Though the mechanism of migraine is complex and unresolved, one hypothesis states repeated activation of the trigeminal vascular system leads to long-term physiological changes. Clinical symptoms include trigeminal allodynia and sensitivity to nitrates, both resulting in pain.
In the original Oshinsky model, an inflammatory soup was infused 3x/week for ~4 weeks, while in this modified version an inflammatory soup was infused over 5 consecutive days. Both methods produce robust facial sensitivity that is persistent at least 6-8 weeks post infusion.
The study illustrated below compares the therapeutic activity of SMTRPTN (IMTRX®), delivered intraperitoneally, to Viridian Pharmaceutical’s proprietary topical formulation of cannabidiol (CBD), delivered transdermally, showing that CBD has slower onset but longer lasting therapeutic activity which exceeds that of SMTRPTN at 3 hours.
Once migraine has been established animals can be used for an additional 4-5 weeks. Therefore, it is possible to test multiple compounds, with a “washout” between compounds, using a given cohort of animals. The inflammatory soup migraine animal model generally takes at least 3-6 weeks to complete depending upon the number of treatment groups and the extent to which animals are used for multiple treatments in a crossover fashion